Sign in
Taking people in FrancePhase 1

Tests etanercept with ultrasound to open the brain barrier in Alzheimer's

Tests etanercept and repeated contrast ultrasound safety in adults with Alzheimer's disease.

Key facts

Who runs it
Fondation Ophtalmologique Adolphe de Rothschild
Where
Paris, FranceSee the site
Trial code
Registry title
Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease
Status
Recruiting
Phase
Phase 1
People taking part
5 people, planned
Started
15 Apr 2025
Expected to end
Dec 2028
Type of study
Interventional
Treatments tested
  • etanercept and repeated contrast ultrasound
Record updated
12 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 to 85 with mild Alzheimer's disease. It tests the safety of etanercept given together with repeated contrast ultrasound.

Age
50 to 85 years
Sex
Men and women can join. Women who have not reached menopause cannot join.
Disease stage
Mild Alzheimer's disease with little or no effect on daily independence, MMSE score of 20 or more, and Fazekas score of 1 or less.
Earlier treatment
If taking anticholinesterase treatment, it must have been stable for at least three months. No earlier treatment with anti-TNF alpha such as etanercept.
Biomarker or test result
A biological profile in favour of Alzheimer's disease.

Main reasons for not taking part

  • Another cause of major neurocognitive disorder
  • Taking anticoagulant therapy
  • Contraindication to MRI or to lumbar puncture
  • Active infection, or hepatitis B or C in the past
  • Epilepsy or major depression despite treatment

The registry criteria, word for word

Show all 46 criteriaShow less

Who can take part

  • Positive diagnosis of Alzheimer's disease according to IWG2 criteria
  • Biological profile in favour of Alzheimer's disease
  • Age ≥ 50 years and ≤ 85 years
  • Affiliated or beneficiary of a social insurance scheme
  • Patient suffering from mild AD with little or no impact on autonomy, MMSE score ≥20 at inclusion
  • Fazekas score <=1
  • Presence of a family or a person at home who can monitor the occurrence of adverse events
  • Sufficient command of the French language to take neuropsychological tests
  • Have undergone a full neuropsychological assessment within 6 months
  • If anticholinesterase treatment, stability of treatment for at least three months
  • Signed, free and informed consent from the patient and the trusted support person

Who cannot take part

  • Patient previously treated with anti-TNF alpha (e.g. etanercept)
  • Participation in another drug study
  • Patient on anticoagulant therapy
  • Treatment with Anakinra, abatacept or sulfasalazine
  • Patients who have undergone major surgery within 28 days of the first day of the study
  • Patients who have undergone major surgery within 28 days of the first day of the study; Contraindications related to etanercept :
  • Other cause of major neurocognitive disorder
  • History of bleeding diathesis
  • Severe chronic respiratory disease
  • Right-to-left shunt, severe pulmonary arterial hypertension
  • Allergy to gadolinium, or any contraindication to contrast products used for brain imaging (in particular severe renal insufficiency with a glomerular filtration rate <30 ml / min / 1.73 m2)
  • Allergy to xylocaine
  • Epilepsy or drugs that lower the epileptogenic threshold (see Appendix 6)
  • Major depressive syndrome despite appropriate treatment and/or psychotic symptoms (according to DSM IV)
  • MRI characteristic of an active or acute neurological process (infection, tumour) or macro-haemorrhage
  • History of hepatitis B or C
  • Patients with recent acute coronary syndrome or unstable ischaemic heart disease
  • History of recurrent or chronic infections, or a predisposing condition such as severe or poorly controlled diabetes
  • Hypersensitivity to etanercept or to any of the excipients of Benepali
  • Active infection including chronic or localised infections; Contraindications associated with SonoVue (ultrasound contrast medium)
  • Hypersensitivity to Sonovue
  • Uncontrolled hypertension
  • Respiratory distress syndrome
  • Conditions suggesting cardiovascular instability for which dobutamine is contraindicated
  • Absolute contraindication to MRI (e.g. pacemaker, implantable stimulator, intra-orbital metallic foreign body)
  • Contraindication to lumbar puncture
  • Known cerebral vasculopathy; (Fazekas greater than 1), sequelae of ACI
  • Non-menopausal women
  • Patient benefiting from a legal protection measure other than guardianship or curatorship
  • Optic neuritis
  • Manifestations of multiple sclerosis
  • Live vaccinations (yellow fever, BCG) within 4 weeks of starting etanercept treatment
  • Sepsis or risk of sepsis
  • Right-to-left shunt
  • Severe PAH (pulmonary arterial pressure greater than 90 mmHg)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 85 years old?

Where in France

  • Fondation Adolphe de RothschldParis, FranceContact: Anne Caroline PAPEIX, MD-PHDTaking people

About the trial

What the trial wants to find out

Alzheimer's disease (AD) is a clinico-pathological entity combining multiple and varied neuropathological lesions with characteristic abnormal accumulations (amyloid Beta (Aβ) plaques and neurofibrillary degeneration (NFD)), neuroinflammation, as well as neuronal and synaptic suffering.

Read full original descriptionShow less

To date, only symptomatic treatments are available, with no proven effect on neuropathological lesions or on the clinical course of the disease.

Anti-TNF alpha could be a therapeutic agent of choice in the treatment of central nervous sytem (CNS) diseases with an inflammatory component, such as AD. Unfortunately, their high molecular weight prevents them from passively crossing the blood brain barrier (BBB). In a pilot study published in 2006, etanercept was administered intrathecally to AD patients with encouraging clinical effects.

Transient opening of the tight junctions between the endothelial cells of the BBB by delivering High Intensity Focalised Ultrasounds (HIFU) in combination with an intravenous injection of microbubbles is a strategy that could improve bioavailability. Studies suggest that the oscillation of microbubbles in the ultrasound field generates microcurrents that induce shear forces responsible for a transient opening of the BBB. Ultrasound can be focused or unfocused and open the BBB diffusely or selectively over defined regions of the brain. This technique was first used to open the BBB in humans in 2001.

Transient opening of the BBB is also thought to modulate the immune response in the CNS, leading to a reduction in the intracerebral load of Aβ. In an Alzheimer's mouse model, several studies using ultrasound devices to open the BBB have shown a reduction in the intracerebral load of Aβ (up to 75%) and an improvement in the memory faculties and cognitive performance of the animals.

In humans, two clinical trials have assessed the safety of using ultrasound-assisted BBB disruption devices in AD patients. These were the Sonocloud® (Carthera) and ExAblate® (InSightec) devices. The Sonocloud® device is an extra-dural ultrasound emitter implanted under local anaesthetic. Enrolment was completed in October 2020, but the results of the trial are not yet available (NCT03119961). The phase I study on 5 patients evaluating the ExAblate® device coupled with the injection of gas microbubbles demonstrated reversible opening of the BBB with no serious adverse effects for the patients. No effect on intracerebral Aβ load or cognitive or behavioural improvement was demonstrated. The ExAblate® device is not implantable and is therefore less invasive than the Sonocloud® device. However, it requires MRI monitoring and the transducers used often generate high levels of heat, requiring the use of a water cooling system to avoid the risk of transducer deterioration.

In this project, our aim is to assess the safety of using a non-focused ultrasound device, the General Electric VIVID S70 clinical device (CE mark G1 023782 0112 ), to perform BBB ruptures in patients suffering from AD, combined with the administration of etanercept, whose bioavailability would thus be improved.

The group in the trial

  • etanercept and repeated contrast ultrasoundTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease: Phase I Study
Plain-language title
Tests etanercept with ultrasound to open the brain barrier in Alzheimer'sGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06585384, who can take part
Record updated
12 May 2026